← Back to Patent Explorer
US5080904A Expired / Lapsed US ⏱️ 0.0 years remaining

Liposome composition and its production

Assignee: Takeda Pharmaceutical Co Ltd
•
Filing: 1989-05-10
•
Granted: 1992-01-14
•
Expires: 2009-05-10
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The liposome compositions entrapping a drug are prepared by constituting the liposomal membrane with a saturated phospholipid and a glycolipid having sulfo group. Thus obtained compositions circulate stably in blood for a long time after intravenous administration.

Inventors

  • 👤 Katsumi Iga
  • 👤 Naoru Hamaguchi
  • 👤 Yasuaki Ogawa

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 12:54
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/20; A61K38/2013; A61K9/00; A61K9/10; A61K9/127; A61K9/1271

Claims Analysis

Total Claims: 10
Claim 1
Independent Claim 126 words
A liposome composition entrapping a drug in liposome of which membrane is constituted by a phospholipid of which the acyl groups thereof are saturated acyl groups and a glycolipid selected from the group consisting of sulfate-containing sulfatosphingoglycolipids, lactosylsulfatides and sulfate-containing sulfatoglyceroglycolipids, said drug being selected from the groups consisting of antitumor agents, lymphokines, physiologically active peptides, antibiotics, vitamins, antiprotozoan drugs, enzymes, anticoagulation agents, antiallergic agents or immunopotentiating agents and wherein said phospholipid has two acyl groups which are saturated alkyls having 8 or more carbon atoms, acyl groups at least one of which is a saturated alkyl group having 10 or more carbon atoms and wherein said glycolipid is present in an amount of 0.5 to 50 parts per 100 parts by weight of said phospholipid.
Claim 2
Dependent Claim 126 words
A liposome composition entrapping a drug in liposome of which membrane is constituted by a phospholipid of which the acyl groups thereof are saturated acyl groups and a glycolipid selected from the group consisting of sulfate-containing sulfatosphingoglycolipids, lactosylsulfatides and sulfate-containing sulfatoglyceroglycolipids, said drug being selected from the groups consisting of antitumor agents, lymphokines, physiologically active peptides, antibiotics, vitamins, antiprotozoan drugs, enzymes, anticoagulation agents, antiallergic agents or immunopotentiating agents and wherein said phospholipid has two acyl groups which are saturated alkyls having 8 or more carbon atoms, acyl groups at least one of which is a saturated alkyl group having 10 or more carbon atoms and wherein said glycolipid is present in an amount of 0.5 to 50 parts per 100 parts by weight of said phospholipid.
Claim 3
Dependent Claim 12 words
The composition according to claim 1, wherein the sulfate-containing sulfatosphingoglycolipid is sulfatide.
Claim 4
Dependent Claim 13 words
The composition according to claim 1, wherein the phospholipids are glycerophopholipids or sphingophospholipids.
Claim 5
Dependent Claim 24 words
The composition according to claim 1, wherein phase transition temperature of the liposomal membrane is in the range of about 40° to 55° C.
Claim 6
Dependent Claim 14 words
The composition according to claim 1, wherein the drug is for drug delivery systems.
Claim 7
Dependent Claim 13 words
The composition according to claim 1, wherein the antitumor agents are platinum compounds.
Claim 8
Dependent Claim 12 words
The composition according to claim 1, wherein the platinum compound is cisplatin.
Claim 9
Dependent Claim 49 words
The composition according to claim 1, wherein the drug is the antitumor agent selected from the group consisting of platinum compounds, adriamycin, mitomycin C, antinomycin, ansamitocin, bleomycin, 5-FU and methotrexate and the phase transition temperature of the liposomal membrane is in the range of about 40° to 55° C.
Claim 10
Dependent Claim 24 words
The composition according to claim 8, wherein the platinum compound is one or more selected from the group consisting of cisplatin, carboplatin and spiroplatin.

References Cited (Backward Citations)

US4782019A Cited
US4619913A Cited
US4880634A Cited
US4818537A Cited
US4837028A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1995-01-13 1995-07-15 1996-01-14 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1999-01-13 1999-07-15 2000-01-14 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2003-01-13 2003-07-15 2004-01-14 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag